| Akcje zaległe | 110,427,682 shares |
| Akcje insidera | 15 272 836 shares |
| Własność insidera | 13,83 % |
| Insiderzy ogółem | 53 |
Wynik sentymentu insiderów
Ocena sentymentu insiderów pokazuje firmy, które są kupowane przez insiderów korporacyjnych.
Jest to wynik zaawansowanego, wieloczynnikowego modelu ilościowego, który identyfikuje spółki o najwyższym poziomie akumulacji informacji poufnych. Model rankingowy wykorzystuje kombinację liczby netto insiderów kupujących w ciągu ostatnich 90 dni, całkowitej liczby akcji kupionych jako procent akcji w obrocie oraz całkowitej liczby akcji posiadanych przez insiderów. Liczba ta waha się od 0 do 100, przy czym wyższe liczby wskazują na wyższy poziom akumulacji w porównaniu z innymi spółkami, a 50 to średnia.
Częstotliwość aktualizacji: codziennie
Ocena sentymentu kadry kierowniczej
Ocena sentymentu kadry kierowniczej pokazuje, że firmy są kupowane przez urzędników korporacyjnych.
Z definicji dyrektorzy korporacyjni to insiderzy korporacyjni, ale w przeciwieństwie do niektórych innych insiderów (10% akcjonariuszy i członków zarządu), dyrektorzy pracują dla firmy na co dzień i podczas handlu korzystają z własnych pieniędzy. (10% Akcjonariusze i członkowie zarządu często zarządzają funduszami zarządzających pieniędzmi innych osób). W związku z tym transakcje wykorzystujące informacje poufne dokonywane przez osoby z kadry kierowniczej mają znacznie większe znaczenie i powinny być odpowiednio traktowane.
Podobnie jak ocena sentymentu insiderów, ocena sentymentu kadry kierowniczej jest wynikiem zaawansowanego, wieloczynnikowego modelu ilościowego, który identyfikuje firmy o najwyższym poziomie akumulacji urzędników.
Częstotliwość aktualizacji: codziennie
Kluczowe wskaźniki insider
Ta karta pokazuje pozycję firmy według różnych wskaźników insider. Ranking według miary percentyla pokazuje, jak ta firma wypada na tle innych firm na rynkach amerykańskich. Wyższe rankingi wskazują na lepszą sytuację.
Na przykład ogólnie przyjmuje się, że kupowanie przez insiderów jest pozytywnym wskaźnikiem, zatem spółki z większą liczbą takich transakcji plasowałyby się wyżej niż spółki z mniejszą liczbą takich transakcji (lub nawet sprzedaży przez insiderów.
Liczba netto zakupów dokonanych przez insiderów (ranking)
404 out of 10948
Liczba netto zakupów dokonanych przez insiderów to łączna liczba insiderów kupujących pomniejszona o całkowitą liczbę insiderów sprzedających w ciągu ostatnich 90 dni. Tutaj pokazana jest miara percentyla (zakres od 0 do 100%).
Procent akcji kupowanych przez insiderów (ranking)
109 out of 10786
Procent akcji zakupionych przez insiderów to całkowita liczba akcji zakupionych przez insiderów pomniejszona o całkowitą liczbę akcji sprzedanych przez insiderów w ciągu ostatnich 90 dni, podzielona przez całkowitą liczbę akcji zakupionych przez insiderów i pomnożona przez 100.
Wykres handlu insider
Poniższy wykres przedstawia Viridian Therapeutics, Inc. transakcji zrealizowanych przez insiderów. Insiderzy to członkowie kadry kierowniczej, dyrektorzy lub znaczący inwestorzy w spółce. Ogólnie rzecz biorąc, dokonywanie transakcji w ich firmach przez osoby posiadające dostęp do informacji poufnych w oparciu o istotne, niepubliczne informacje jest generalnie nielegalne. Nie oznacza to, że dokonywanie jakichkolwiek transakcji we własnych firmach jest nielegalne. Muszą jednak zgłaszać wszystkie transakcje do SEC za pośrednictwem formularza 4.
Lista insiderów i wskaźniki rentowności
Ta tabela przedstawia listę znanych insiderów i jest generowana automatycznie na podstawie zgłoszeń ujawnianych SEC. Oprócz nazwisk, najnowszego tytułu oraz oznaczenia dyrektora, członka kierownictwa lub 10% właściciela, podajemy najnowsze ujawnione pakiety akcji. Dodatkowo, jeśli to możliwe, udostępniamy historyczne wyniki handlowe danego insidera. Historyczne wyniki handlowe to średnia ważona wyników rzeczywistych transakcji zakupu na otwartym rynku dokonanych przez insiderów. Więcej informacji na temat sposobu obliczania tej wartości obejrzyj webinar na YouTube.
See our leaderboard of most profitable insider traders.
| Insider | Średni zysk (%) | Posiadane Akcje |
Podział korygujący |
|---|---|---|---|
|
Atlas Venture Fund VII L P
10% Owner -
|
6 285 160 | 419 011 | |
| Beetham Thomas W. Chief Operating Officer - [O] | 13 361 | 13 361 | |
| Bruce Booth Director - [D] | 1 351 090 | 90 073 | |
| Christopher Bowden | 24 000 | ||
|
Cohen Steven A/sac Capital Mgmt Lp
10% Owner -
|
426 162 | 426 162 | |
| Thomas Ciulla Chief Medical Officer - [O] | 762 | 762 | |
| John W Creecy Director - [D] | 5 413 126 | 360 875 | |
| Diana Escolar | 270 000 | ||
|
Fhmlsp, L.l.c.
10% Owner -
|
1 505 200 | 1 505 200 | |
|
Fhmlsp, L.p.
10% Owner -
|
1 505 200 | 1 505 200 | |
|
Fairmount Funds Management LLC
Director, 10% Owner -
[D]
|
5 090 928 | 5 090 928 | |
| Fairmount Healthcare Fund GP LLC Director - [D] | 938 233 | 1 845 813 | |
| Fairmount Healthcare Fund II GP LLC Director - [D] | 938 233 | 5 090 928 | |
| Fairmount Healthcare Fund II L.P. Director - [D] | 938 233 | 5 090 928 | |
| Fairmount Healthcare Fund L.P. Director - [D] | 938 233 | 1 845 813 | |
|
Frazier Life Sciences Public Fund, L.P.
10% Owner -
|
1 505 200 | 1 505 200 | |
| David A Gonyer Director - [D] | 1 899 | 1 899 |
| Insider | Średni zysk (%) | Posiadane Akcje |
Podział korygujący |
|---|---|---|---|
| Seth Harmon Chief Financial Officer - [O] | 7 850 | 7 850 | |
| Peter Evan Harwin | 24 000 | ||
| Hatfield Jeffrey S. | 24 000 | ||
| Hughes Thomas E. Director - [D] | 12 827 | 855 | |
| Kristian Humer | 90 000 | ||
| Robert Brian Johnson | 0 | ||
| Kevin Koch | 24 000 | ||
| Barrett Katz Chief Medical Officer - [O] | 0 | 0 | |
| Tomas Kiselak | 24 000 | ||
|
Peter Kolchinsky
10% Owner -
|
410 686 | 410 686 | |
|
Alpha, Lllp Lebow
10% Owner -
|
4 465 258 | 4 465 258 | |
|
Bennett S Lebow
Director, 10% Owner -
[D]
|
280 600 | 18 707 | |
| Kyle Lefkoff Director - [D] | 463 473 | 30 898 | |
| Leverone Jason A. CFO, Treasurer & Secretary - [O] | 48 829 | 3 255 | |
| Adam Scott Levy Chief Business Officer - [O] | 10 540 | 703 | |
|
Logos Global Master Fund LP
10% Owner -
|
550 000 | 550 000 | |
| Mahoney Stephen F. President and CEO, Director - [D] [O] | 33 349 | 33 349 | |
| William Stuart Marshall President & CEO, Director - [D] [O] | 270 646 | 18 043 |
| Insider | Średni zysk (%) | Posiadane Akcje |
Podział korygujący |
|---|---|---|---|
| Lara Meisner Chief Legal Officer - [O] | 29 971 | 29 971 | |
| Arlene Morris | 24 000 | ||
| Scott Dunseth Myers Chief Executive Officer, Director - [D] [O] | 259 500 | 259 500 | |
|
Point72 Asset Management, L.P.
10% Owner -
|
426 162 | 426 162 | |
|
Point72 Capital Advisors, Inc.
10% Owner -
|
426 162 | 426 162 | |
|
Ra Capital Management, Llc
10% Owner -
|
410 686 | 410 686 | |
|
RA Capital Healthcare Fund LP
10% Owner -
|
410 686 | 410 686 | |
| Paul D Rubin | 87 000 | ||
| Rauch Lee M. | 900 000 | ||
|
Remeditex Ventures LLC
10% Owner -
|
5 413 126 | 360 875 | |
| Samuel D Riccitelli President & CEO, Director - [D] [O] | 571 370 | 571 370 | |
| Tamara A Seymour CFO, Secretary, Treasurer - [O] | 106 447 | 106 447 | |
| Douglas A Schuling Director - [D] | 10 500 | 10 500 | |
|
Shah Rajeev M.
10% Owner -
|
410 686 | 410 686 | |
| Robin L Smith Director - [D] | 1 900 | 1 900 | |
| Joseph L Turner | 24 000 | ||
| Jennifer Tousignant Chief Legal Officer - [O] | 3 494 | 3 494 | |
| Jonathan Violin Chief Executive Officer, Director - [D] [O] | 480 905 | 480 905 |
Report errors via our new Insider Auditing Tool
Śledź historię zakupów insiderów — analiza zysków krótkoterminowych
W tej sekcji analizujemy rentowność każdego nieplanowanego zakupu od poufnych informacji na otwartym rynku dokonanego w VRDN / Viridian Therapeutics, Inc.. Analiza ta pomaga zrozumieć, czy insider konsekwentnie generuje nietypowe zyski i czy warto ją śledzić. Analiza ta obejmuje okres jednego roku po każdej transakcji wyniki są teoretyczne .
Poniższa tabela przedstawia najnowsze zakupy na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Śledź historię sprzedaży insider — analiza strat krótkoterminowych
W tej sekcji analizujemy możliwość uniknięcia krótkoterminowych strat w wyniku każdej nieplanowanej sprzedaży insidera na otwartym rynku dokonanej w VRDN / Viridian Therapeutics, Inc.. Konsekwentny wzorzec unikania strat może sugerować, że przyszłe transakcje sprzedaży mogą przewidywać spadki cen. Analiza ta obejmuje okres jednego roku po każdej transakcji wyniki są teoretyczne .
Poniższa tabela przedstawia najnowsze sprzedaże na otwartym rynku, które nie były częścią planu handlu automatycznego.
Cena skorygowana to cena skorygowana o podział. Akcje skorygowane to akcje skorygowane o podział.
Historia transakcji
Kliknij ikonę linku, aby zobaczyć pełną historię transakcji. Transakcje zgłoszone w ramach automatycznego planu handlowego 10b5-1 będą oznaczone znakiem X w kolumnie oznaczonej 10b-5.
| Plik Data |
Data transakcji |
Formularz | Wtajemniczony | Serce | Nazwa papieru wartościowego | Kod | Bezpośredni | Cena wykonania |
Cena jednostki |
Zmieniono jednostki |
Zmieniona wartość (1 tys.) |
Pozostałe opcje |
Pozostałe akcje |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | 2026-05-11 | 4 | Fairmount Funds Management LLC By Fairmount Healthcare Fund II L.P. | VRDN | Common Stock | I | 17,0000 | 1 176 470 | 20 000 | 5 090 928 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Harmon Seth | VRDN | Common Stock | D | 30,1900 | -2 031 | -61 | 7 850 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Beetham Thomas W. | VRDN | Common Stock | D | 30,1900 | -3 048 | -92 | 13 361 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Mahoney Stephen F. | VRDN | Common Stock | D | 30,1900 | -7 408 | -224 | 33 349 | ||||
| 2026-03-09 | 2026-03-03 | 4/A | Tousignant Jennifer | VRDN | Common Stock | D | 30,1900 | -1 675 | -51 | 3 494 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Tousignant Jennifer | VRDN | Common Stock | D | 29,3200 | -1 724 | -51 | 3 445 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Tousignant Jennifer | VRDN | Common Stock | D | 5 169 | 5 169 | ||||||
| 2026-03-04 | 2026-03-03 | 4 | Harmon Seth | VRDN | Common Stock | D | 29,3200 | -2 091 | -61 | 7 790 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Harmon Seth | VRDN | Common Stock | D | 6 267 | 9 881 | ||||||
| 2026-03-04 | 2026-03-03 | 4 | Beetham Thomas W. | VRDN | Common Stock | D | 29,3200 | -3 138 | -92 | 13 271 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Beetham Thomas W. | VRDN | Common Stock | D | 9 409 | 16 409 | ||||||
| 2026-03-04 | 2026-03-03 | 4 | Mahoney Stephen F. | VRDN | Common Stock | D | 29,3200 | -7 627 | -224 | 33 130 | ||||
| 2026-03-04 | 2026-03-03 | 4 | Mahoney Stephen F. | VRDN | Common Stock | D | 18 357 | 40 757 | ||||||
| 2026-01-02 | 2025-12-31 | 4 | Tousignant Jennifer | VRDN | Common Stock | D | 31,1600 | -2 272 | -71 | 0 | ||||
| 2025-10-27 | 2025-10-23 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 22,0000 | 454 545 | 10 000 | 3 914 458 | ||||
| 2025-06-11 | 2025-06-10 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 12,3100 | 12 500 | 154 | 3 459 913 | ||||
| 2025-06-11 | 2025-06-09 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 7,8000 | 1 600 | 12 | 3 447 413 | ||||
| 2024-09-30 | 2024-09-27 | 4 | Beetham Thomas W. | VRDN | Common Stock | D | 23,4100 | 5 000 | 117 | 6 000 | ||||
| 2024-09-30 | 2024-09-27 | 4 | Mahoney Stephen F. | VRDN | Common Stock | D | 23,3300 | 21 400 | 499 | 21 400 | ||||
| 2024-09-17 | 2024-09-13 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 18,7500 | 1 600 000 | 30 000 | 3 445 813 | ||||
| 2024-04-01 | 2024-03-28 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 5 859 | 1 845 813 | ||||||
| 2024-04-01 | 2024-03-28 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | VRDN | Common Stock | I | -5 859 | 0 | ||||||
| 2024-01-24 | 2024-01-22 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 21,0000 | 476 190 | 10 000 | 1 839 954 | ||||
| 2024-01-12 | 3 | Ciulla Thomas | VRDN | Common Stock | D | 762 | ||||||||
| 2023-06-20 | 2023-06-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,3500 | -27 | -1 | 29 971 | ||||
| 2023-06-20 | 2023-06-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 27 | 1 | 29 998 | ||||
| 2023-06-20 | 2023-06-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0200 | -2 269 | -64 | 29 971 | ||||
| 2023-06-20 | 2023-06-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 2 269 | 52 | 32 240 | ||||
| 2023-06-06 | 2023-06-06 | 4 | Meisner Lara | VRDN | Common Stock | D | 25,0200 | -5 126 | -128 | 29 971 | ||||
| 2023-06-06 | 2023-06-06 | 4 | Meisner Lara | VRDN | Common Stock | D | 18,5100 | 5 126 | 95 | 35 097 | ||||
| 2023-06-06 | 2023-06-05 | 4 | Meisner Lara | VRDN | Common Stock | D | 25,0300 | -499 | -12 | 29 971 | ||||
| 2023-06-06 | 2023-06-05 | 4 | Meisner Lara | VRDN | Common Stock | D | 18,5100 | 499 | 9 | 30 470 | ||||
| 2023-06-06 | 2023-06-02 | 4 | Meisner Lara | VRDN | Common Stock | D | 24,2100 | -1 875 | -45 | 29 971 | ||||
| 2023-06-06 | 2023-06-02 | 4 | Meisner Lara | VRDN | Common Stock | D | 14,0000 | 1 875 | 26 | 31 846 | ||||
| 2023-04-12 | 2023-04-12 | 4 | Myers Scott Dunseth | VRDN | Common Stock | D | 25,3697 | 4 000 | 101 | 259 500 | ||||
| 2023-03-13 | 2023-03-13 | 4 | Myers Scott Dunseth | VRDN | Common Stock | D | 29,1499 | 5 500 | 160 | 255 500 | ||||
| 2023-03-10 | 2023-03-09 | 4 | Meisner Lara | VRDN | Common Stock | D | 29,0700 | -29 971 | -871 | 0 | ||||
| 2023-02-07 | 2023-02-06 | 4 | Myers Scott Dunseth | VRDN | Common Stock | D | 250 000 | 250 000 | ||||||
| 2023-02-07 | 2023-02-02 | 4/A | Violin Jonathan | VRDN | Common Stock | D | 36,8000 | -50 000 | -1 840 | 480 905 | ||||
| 2023-02-07 | 2023-02-02 | 4/A | Violin Jonathan | VRDN | Common Stock | D | 0,1500 | 50 000 | 8 | 530 905 | ||||
| 2023-02-03 | 2023-02-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 36,8000 | -50 000 | -1 840 | 430 905 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Meisner Lara | VRDN | Common Stock | D | 35,6600 | -6 843 | -244 | 0 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Meisner Lara | VRDN | Common Stock | D | 14,0000 | 1 872 | 26 | 6 843 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 4 971 | 114 | 4 971 | ||||
| 2023-01-18 | 2023-01-17 | 4 | Katz Barrett | VRDN | Common Stock | D | 37,2100 | -24 853 | -925 | 0 | ||||
| 2023-01-18 | 2023-01-17 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 24 853 | 572 | 24 853 | ||||
| 2023-01-18 | 2023-01-13 | 4 | Katz Barrett | VRDN | Common Stock | D | 37,0100 | -4 147 | -153 | 0 | ||||
| 2023-01-18 | 2023-01-13 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 4 147 | 96 | 4 147 | ||||
| 2023-01-11 | 2023-01-10 | 4 | Katz Barrett | VRDN | Common Stock | D | 35,3000 | -47 377 | -1 672 | 0 | ||||
| 2023-01-11 | 2023-01-10 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 47 377 | 1 091 | 47 377 | ||||
| 2023-01-11 | 2023-01-09 | 4 | Katz Barrett | VRDN | Common Stock | D | 33,0400 | -12 623 | -417 | 0 | ||||
| 2023-01-11 | 2023-01-09 | 4 | Katz Barrett | VRDN | Common Stock | D | 23,0300 | 12 623 | 291 | 12 623 | ||||
| 2022-12-22 | 2022-12-21 | 4 | Meisner Lara | VRDN | Common Stock | D | 29,1900 | -16 326 | -477 | 0 | ||||
| 2022-12-22 | 2022-12-21 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 16 326 | 376 | 16 326 | ||||
| 2022-12-22 | 2022-12-20 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0700 | -600 | -17 | 0 | ||||
| 2022-12-22 | 2022-12-20 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 600 | 14 | 600 | ||||
| 2022-12-19 | 2022-12-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,4400 | -1 297 | -37 | 0 | ||||
| 2022-12-19 | 2022-12-16 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 1 297 | 30 | 1 297 | ||||
| 2022-12-19 | 2022-12-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0800 | -300 | -8 | 0 | ||||
| 2022-12-19 | 2022-12-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 300 | 7 | 300 | ||||
| 2022-12-14 | 2022-12-14 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,1200 | -15 656 | -440 | 0 | ||||
| 2022-12-14 | 2022-12-14 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 15 656 | 361 | 15 656 | ||||
| 2022-12-14 | 2022-12-12 | 4 | Meisner Lara | VRDN | Common Stock | D | 28,0500 | -600 | -17 | 0 | ||||
| 2022-12-14 | 2022-12-12 | 4 | Meisner Lara | VRDN | Common Stock | D | 23,0300 | 600 | 14 | 600 | ||||
| 2022-11-16 | 2022-11-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 22,0500 | -8 125 | -179 | 0 | ||||
| 2022-11-16 | 2022-11-15 | 4 | Meisner Lara | VRDN | Common Stock | D | 14,0000 | 8 125 | 114 | 8 125 | ||||
| 2022-08-19 | 2022-08-17 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 23,5000 | 425 531 | 10 000 | 1 363 764 | ||||
| 2022-06-02 | 2022-06-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 12,2000 | -30 000 | -366 | 480 905 | ||||
| 2022-05-04 | 2022-05-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 13,0400 | -30 000 | -391 | 510 905 | ||||
| 2022-04-05 | 2022-04-04 | 4 | Violin Jonathan | VRDN | Common Stock | D | 18,9300 | -3 600 | -68 | 540 905 | ||||
| 2022-04-05 | 2022-04-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 18,9200 | -26 400 | -499 | 544 505 | ||||
| 2022-03-03 | 2022-03-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 17,3600 | -11 106 | -193 | 570 905 | ||||
| 2022-03-03 | 2022-03-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 17,8200 | -18 894 | -337 | 582 011 | ||||
| 2022-02-03 | 2022-02-02 | 4 | Humer Kristian | VRDN | Stock Option (Right to Buy) | D | 18,51 | 90 000 | 90 000 | |||||
| 2022-02-03 | 2022-02-02 | 4 | Katz Barrett | VRDN | Stock Option (Right to Buy) | D | 18,51 | 110 000 | 110 000 | |||||
| 2022-02-03 | 2022-02-02 | 4 | Meisner Lara | VRDN | Stock Option (Right to Buy) | D | 18,51 | 90 000 | 90 000 | |||||
| 2022-02-03 | 2022-02-03 | 4 | Violin Jonathan | VRDN | Common Stock | D | 19,1600 | -909 | -17 | 600 905 | ||||
| 2022-02-03 | 2022-02-02 | 4 | Violin Jonathan | VRDN | Stock Option (Right to Buy) | D | 18,51 | 280 000 | 280 000 | |||||
| 2022-02-03 | 2022-02-02 | 4 | Violin Jonathan | VRDN | Common Stock | D | 18,4700 | -12 340 | -228 | 601 814 | ||||
| 2022-02-03 | 2022-02-01 | 4 | Violin Jonathan | VRDN | Common Stock | D | 19,5500 | -16 751 | -327 | 614 154 | ||||
| 2022-01-03 | 2021-12-31 | 4 | Humer Kristian | VRDN | Stock Option (Right to Buy) | D | 19,77 | 121 371 | 121 371 | |||||
| 2021-12-10 | 2021-12-08 | 4 | Violin Jonathan | VRDN | Series A Non-Voting Convertible Preferred Stock | D | -9 413 | 0 | ||||||
| 2021-12-10 | 2021-12-08 | 4 | Violin Jonathan | VRDN | Common Stock | D | 627 564 | 630 905 | ||||||
| 2021-09-28 | 2021-09-23 | 4 | Frazier Life Sciences Public Fund, L.P. | VRDN | Common Stock | D | 11,0000 | 200 000 | 2 200 | 1 505 200 | ||||
| 2021-09-23 | 2021-09-21 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | VRDN | Common Stock | I | 11,0000 | 909 000 | 9 999 | 938 233 | ||||
| 2021-08-26 | 3 | FHMLSP, L.P. | VRDN | Common Stock | D | 1 305 200 | ||||||||
| 2021-07-27 | 2021-07-26 | 4 | Humer Kristian | VRDN | Stock Option (Right to Buy) | D | 17,09 | 360 000 | 360 000 | |||||
| 2021-07-15 | 2021-07-14 | 4 | Moses Jennifer K. | VRDN | Stock Option (Right to Buy) | D | 17,88 | 25 000 | 25 000 | |||||
| 2021-06-16 | 2021-06-03 | 4 | Kiselak Tomas | VRDN | Stock Option (Right to Buy) | D | 16,60 | 12 500 | 12 500 | |||||
| 2021-06-16 | 2021-06-03 | 4 | Harwin Peter Evan | VRDN | Stock Option (Right to Buy) | D | 16,60 | 12 500 | 12 500 | |||||
| 2021-06-16 | 2021-06-03 | 4 | Morris Arlene | VRDN | Stock Option (Right to Buy) | D | 16,60 | 12 500 | 12 500 | |||||
| 2021-02-08 | 2021-02-04 | 4 | TURNER JOSEPH L | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25 000 | 25 000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Harwin Peter Evan | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25 000 | 25 000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Hatfield Jeffrey S. | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25 000 | 25 000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Kiselak Tomas | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25 000 | 25 000 | |||||
| 2021-02-08 | 2021-02-04 | 4 | Morris Arlene | VRDN | Director Stock Option (Right to Buy) | D | 20,50 | 25 000 | 25 000 | |||||
| 2021-01-21 | 2021-01-18 | 4 | Katz Barrett | VRDN | Employee Stock Option (right to buy) | D | 23,03 | 356 000 | 356 000 | |||||
| 2021-01-20 | 2021-01-18 | 4 | Leverone Jason A. | VRDN | Employee Stock Option (right to buy) | D | 23,03 | 311 785 | 311 785 | |||||
| 2021-01-20 | 2021-01-18 | 4 | Violin Jonathan | VRDN | Employee Stock Option (right to buy) | D | 23,03 | 800 075 | 800 075 | |||||
| 2021-01-19 | 2021-01-18 | 4 | Rauch Lee M. | MGEN | Employee Stock Option (right to buy) | D | 23,03 | 15 000 | 15 000 | |||||
| 2020-12-17 | 3 | Shah Rajeev M. | MGEN | Common Stock | I | 410 686 | ||||||||
| 2020-11-20 | 3 | COHEN STEVEN A/SAC CAPITAL MGMT LP See footnotes | MGEN | Common Stock | I | 426 162 | ||||||||
| 2020-11-16 | 2020-11-13 | 4 | Logos Global Master Fund LP | MGEN | Common Stock | D | 14,8389 | 126 667 | 1 880 | 550 000 | ||||
| 2020-11-16 | 2020-11-09 | 4 | Logos Global Master Fund LP | MGEN | Common Stock | D | 1,1641 | 100 000 | 116 | 6 350 000 | ||||
| 2020-11-16 | 2020-11-09 | 4 | Logos Global Master Fund LP | MGEN | Common Stock | D | 1,0979 | 250 000 | 274 | 6 250 000 | ||||
| 2020-11-16 | 3 | Logos Global Master Fund LP | MGEN | Common Stock | D | 6 000 000 | ||||||||
| 2020-10-30 | 2020-10-27 | 4 | Violin Jonathan | MGEN | Series A Non-Voting Convertible Preferred Stock | D | 9 413 | 9 413 | ||||||
| 2020-10-30 | 2020-10-27 | 4 | Violin Jonathan | MGEN | Employee Stock Option (Right to Buy) | D | 0,01 | 4 338 079 | 4 338 079 | |||||
| 2020-10-30 | 2020-10-27 | 4 | Violin Jonathan | MGEN | Common Stock | D | 50 124 | 50 124 | ||||||
| 2020-10-30 | 3 | Violin Jonathan | MGEN | Common Stock | D | 50 124 | ||||||||
| 2020-10-30 | 2020-10-30 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 465,9600 | 28 843 | 13 440 | 111 192 | ||||
| 2020-10-30 | 2020-10-30 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 465,9600 | 5 494 | 2 560 | 21 999 | ||||
| 2020-10-30 | 3 | Fairmount Healthcare Fund II L.P. By funds | MGEN | Common Stock | I | 526 393 | ||||||||
| 2020-10-29 | 2020-10-27 | 4 | Kiselak Tomas | MGEN | Director Stock Option (Right to Buy) | D | 0,52 | 24 000 | 24 000 | |||||
| 2020-10-29 | 2020-10-27 | 4 | Harwin Peter Evan | MGEN | Director Stock Option (Right to Buy) | D | 0,52 | 24 000 | 24 000 | |||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 82 349 | 82 349 | ||||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | MGEN | Series A Non-Voting Convertible Preferred Stock | I | 16 505 | 16 505 | ||||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund II LP | MGEN | Common Stock | I | 438 502 | 438 502 | ||||||
| 2020-10-29 | 2020-10-27 | 4 | Fairmount Funds Management LLC Fairmount Healthcare Fund LP | MGEN | Common Stock | I | 87 891 | 87 891 | ||||||
| 2020-09-17 | 2020-09-13 | 4/A | Rauch Lee M. | MGEN | Stock Option (right to buy) | D | 0,91 | 900 000 | 900 000 | |||||
| 2020-09-15 | 2020-09-14 | 4 | Rauch Lee M. | MGEN | Stock Option (right to buy) | D | 0,91 | 900 000 | 900 000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Hatfield Jeffrey S. | MGEN | Stock Option (right to buy) | D | 0,63 | 24 000 | 24 000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 0,63 | 24 000 | 24 000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 0,63 | 24 000 | 24 000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 0,63 | 24 000 | 24 000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Morris Arlene | MGEN | Stock Option (right to buy) | D | 0,63 | 24 000 | 24 000 | |||||
| 2020-05-22 | 2020-05-21 | 4 | Bowden Christopher | MGEN | Stock Option (right to buy) | D | 0,63 | 24 000 | 24 000 | |||||
| 2020-03-17 | 2020-03-13 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,57 | -11 249 | 0 | |||||
| 2020-03-17 | 2020-03-13 | 4 | Leverone Jason A. | MGEN | Common Stock | D | 0,5700 | 11 249 | 6 | 48 829 | ||||
| 2020-02-14 | 2020-02-12 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 0,80 | 464 000 | 464 000 | |||||
| 2020-02-14 | 2020-02-12 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,80 | 185 000 | 185 000 | |||||
| 2020-02-14 | 2020-02-12 | 4 | Escolar Diana | MGEN | Stock Option (right to buy) | D | 0,80 | 270 000 | 270 000 | |||||
| 2020-02-13 | 2019-08-21 | 5 | Marshall William Stuart | MGEN | Common Stock | D | 1,1390 | 1 250 | 1 | 270 646 | ||||
| 2020-02-13 | 2019-02-21 | 5 | Marshall William Stuart | MGEN | Common Stock | D | 2,4565 | 1 250 | 3 | 269 396 | ||||
| 2019-08-23 | 2019-08-23 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,57 | -3 093 | 0 | |||||
| 2019-08-23 | 2019-08-23 | 4 | Leverone Jason A. | MGEN | Common Stock | D | 0,5700 | 3 093 | 2 | 36 330 | ||||
| 2019-06-21 | 2019-06-19 | 4 | Bowden Christopher | MGEN | Stock Option (right to buy) | D | 2,36 | 12 000 | 12 000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | Hatfield Jeffrey S. | MGEN | Stock Option (right to buy) | D | 2,36 | 12 000 | 12 000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 2,36 | 12 000 | 12 000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 2,36 | 12 000 | 12 000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | Morris Arlene | MGEN | Stock Option (right to buy) | D | 2,36 | 12 000 | 12 000 | |||||
| 2019-06-21 | 2019-06-19 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 2,36 | 12 000 | 12 000 | |||||
| 2019-04-05 | 2019-04-03 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 2,99 | 10 106 | 10 106 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 2,96 | 232 000 | 232 000 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 2,96 | 75 000 | 75 000 | |||||
| 2019-02-08 | 2019-02-06 | 4 | Levy Adam Scott | MGEN | Stock Option (right to buy) | D | 2,96 | 74 000 | 74 000 | |||||
| 2019-02-08 | 2019-02-06 | 4 | RUBIN PAUL D | MGEN | Stock Option (right to buy) | D | 2,96 | 87 000 | 87 000 | |||||
| 2018-10-12 | 2018-10-11 | 4 | Hughes Thomas E. | MGEN | Common Stock | D | 4,7697 | 10 000 | 48 | 12 827 | ||||
| 2018-08-09 | 2018-08-07 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 0,57 | -29 530 | 0 | |||||
| 2018-08-09 | 2018-08-07 | 4 | Leverone Jason A. | MGEN | Common Stock | D | 0,5700 | 29 530 | 17 | 30 737 | ||||
| 2018-06-28 | 2018-06-27 | 4 | Morris Arlene | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Bowden Christopher | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Hatfield Jeffrey S. | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-06-28 | 2018-06-27 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 6,46 | 12 000 | 12 000 | |||||
| 2018-02-15 | 2018-02-13 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 0,57 | -115 818 | 0 | |||||
| 2018-02-15 | 2018-02-13 | 4 | Marshall William Stuart | MGEN | Common Stock | D | 0,5700 | 115 818 | 66 | 265 646 | ||||
| 2018-02-13 | 2018-02-13 | 4 | Booth Bruce | MGEN | Common Stock | I | 5,5000 | 545 454 | 3 000 | 1 351 090 | ||||
| 2018-02-13 | 2018-02-13 | 4 | Levy Adam Scott | MGEN | Common Stock | D | 5,5000 | 9 090 | 50 | 10 540 | ||||
| 2018-02-02 | 2018-01-31 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 7,50 | 245 000 | 245 000 | |||||
| 2018-02-02 | 2018-01-31 | 4 | RUBIN PAUL D | MGEN | Stock Option (right to buy) | D | 7,50 | 85 000 | 85 000 | |||||
| 2018-02-02 | 2018-01-31 | 4 | Levy Adam Scott | MGEN | Stock Option (right to buy) | D | 7,50 | 80 000 | 80 000 | |||||
| 2018-02-02 | 2018-01-31 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 7,50 | 75 000 | 75 000 | |||||
| 2018-01-05 | 2018-01-03 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 9,72 | 10 191 | 10 191 | |||||
| 2018-01-05 | 2018-01-03 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 9,72 | 3 426 | 3 426 | |||||
| 2017-12-22 | 2017-12-20 | 4 | Hughes Thomas E. | MGEN | Common Stock | D | 8,0000 | -12 000 | -96 | 2 827 | ||||
| 2017-06-30 | 2017-06-28 | 4 | KOCH KEVIN | MGEN | Stock Option (right to buy) | D | 12,06 | 12 000 | 12 000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | LEFKOFF KYLE | MGEN | Stock Option (right to buy) | D | 12,06 | 12 000 | 12 000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 12,06 | 12 000 | 12 000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 12,06 | 12 000 | 12 000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | Creecy John W | MGEN | Stock Option (right to buy) | D | 12,06 | 12 000 | 12 000 | |||||
| 2017-06-30 | 2017-06-28 | 4 | TURNER JOSEPH L | MGEN | Stock Option (right to buy) | D | 12,06 | 12 000 | 12 000 | |||||
| 2017-06-23 | 2017-06-22 | 4 | Levy Adam Scott | MGEN | Common Stock | D | 7,5500 | 200 | 2 | 200 | ||||
| 2017-03-28 | 2017-03-24 | 4 | Booth Bruce | MGEN | Stock Option (right to buy) | D | 11,80 | 6 844 | 6 844 | |||||
| 2017-03-28 | 2017-03-24 | 4 | Hughes Thomas E. | MGEN | Stock Option (right to buy) | D | 11,80 | 1 191 | 1 191 | |||||
| 2017-03-28 | 2017-03-24 | 4 | Hughes Thomas E. | MGEN | Common Stock | D | 778 | 14 840 | ||||||
| 2017-03-13 | 2017-03-10 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,3118 | -3 300 | -47 | 463 473 | ||||
| 2017-03-13 | 2017-03-09 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,3846 | -2 500 | -36 | 466 773 | ||||
| 2017-03-08 | 2017-03-08 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,7028 | -5 000 | -74 | 469 273 | ||||
| 2017-03-08 | 2017-03-06 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 16,2398 | -608 | -10 | 474 273 | ||||
| 2017-03-08 | 2017-03-06 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 15,7144 | -9 392 | -148 | 474 881 | ||||
| 2017-02-28 | 2017-02-28 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 13,5430 | -2 258 | -31 | 484 273 | ||||
| 2017-02-28 | 2017-02-27 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 13,7910 | -1 500 | -21 | 486 531 | ||||
| 2017-02-28 | 2017-02-24 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,0388 | -6 500 | -91 | 488 031 | ||||
| 2017-02-24 | 2017-02-23 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 13,6477 | -1 800 | -25 | 494 531 | ||||
| 2017-02-24 | 2017-02-22 | 4 | LEFKOFF KYLE | MGEN | Common Stock | I | 14,3554 | -4 102 | -59 | 496 331 | ||||
| 2017-02-16 | 2017-02-16 | 4 | RUBIN PAUL D | MGEN | Stock Option (right to buy) | D | 11,01 | 87 500 | 87 500 | |||||
| 2017-02-16 | 2017-02-16 | 4 | Leverone Jason A. | MGEN | Stock Option (right to buy) | D | 11,01 | 77 500 | 77 500 | |||||
| 2017-02-16 | 2017-02-16 | 4 | Marshall William Stuart | MGEN | Stock Option (right to buy) | D | 11,01 | 200 000 | 200 000 | |||||
| 2017-02-16 | 2017-02-16 | 4 | Levy Adam Scott | MGEN | Stock Option (right to buy) | D | 11,01 | 87 500 | 87 500 | |||||
| 2017-02-13 | 3 | Creecy John W | MGEN | Common Stock | I | 5 413 126 | ||||||||
| 2017-02-13 | 3 | Creecy John W | MGEN | Common Stock | I | 5 413 126 | ||||||||
| 2017-02-13 | 3 | Remeditex Ventures LLC | MGEN | Common Stock | D | 5 413 126 | ||||||||
| 2017-02-13 | 3 | Remeditex Ventures LLC | MGEN | Common Stock | D | 5 413 126 | ||||||||
| 2017-02-13 | 3 | Atlas Venture Fund VII L P | MGEN | Common Stock | D | 6 285 160 | ||||||||
| 2017-02-13 | 3 | Atlas Venture Fund VII L P | MGEN | Common Stock | D | 6 285 160 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 2 608 303 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 2 608 303 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 3 715 307 | ||||||||
| 2017-02-13 | 3 | LEFKOFF KYLE See Footnotes | MGEN | Common Stock | I | 3 715 307 | ||||||||
| 2017-02-13 | 3 | Marshall William Stuart | MGEN | Common Stock | D | 297 156 | ||||||||
| 2017-02-13 | 3 | Marshall William Stuart | MGEN | Common Stock | D | 297 156 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 7 090 796 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 7 090 796 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 4 753 852 | ||||||||
| 2017-02-13 | 3 | Booth Bruce | MGEN | Common Stock | I | 4 753 852 | ||||||||
| 2017-02-13 | 3 | Hughes Thomas E. | MGEN | Common Stock | D | 28 124 | ||||||||
| 2017-02-13 | 3 | Hughes Thomas E. | MGEN | Common Stock | D | 28 124 | ||||||||
| 2017-02-13 | 2017-02-13 | 4 | LEBOW BENNETT S | MGEN | Unsecured Demand Promissory Note | D | 5,39 | 0 | ||||||
| 2017-02-13 | 2017-02-13 | 4 | LEBOW BENNETT S | MGEN | Unsecured Demand Promissory Note | D | 5,39 | |||||||
| 2017-02-13 | 2017-02-13 | 4 | LEBOW BENNETT S | MGEN | Common Stock | D | 5,3900 | 279 067 | 1 504 | 280 600 | ||||
| 2017-02-08 | 2017-02-08 | 4 | Gonyer David A | SGNL | Stock Option (Right to Buy) | D | 7,65 | -1 200 | 0 | |||||
| 2017-02-08 | 2017-02-08 | 4 | Gonyer David A | SGNL | Common Stock | D | 7,6500 | 1 200 | 9 | 1 899 | ||||
| 2017-02-07 | 2017-02-03 | 4 | Smith Robin L | SGNL | Stock Option (Right to Buy) | D | 7,65 | -1 200 | 0 | |||||
| 2017-02-07 | 2017-02-03 | 4 | Smith Robin L | SGNL | Common Stock | D | 7,6500 | 1 200 | 9 | 1 900 | ||||
| 2017-02-07 | 2017-02-03 | 4 | LEBOW BENNETT S | SGNL | Stock Option (Right to Buy) | D | 7,65 | -1 200 | 0 | |||||
| 2017-02-07 | 2017-02-03 | 4 | LEBOW BENNETT S | SGNL | Common Stock | D | 7,6500 | 1 200 | 9 | 1 533 | ||||
| 2016-11-02 | 2016-10-31 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | -200 000 | 0 | |||||
| 2016-11-02 | 2016-10-31 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,3600 | -103 160 | -37 | 571 370 | ||||
| 2016-11-02 | 2016-10-31 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 200 000 | 674 530 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -100 000 | 0 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -46 000 | 0 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 0,3600 | -45 580 | -16 | 106 447 | ||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 100 000 | 152 027 | ||||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 0,3600 | -20 967 | -8 | 52 027 | ||||
| 2016-11-02 | 2016-10-31 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 46 000 | 72 994 | ||||||
| 2016-08-10 | 2016-08-08 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -23 000 | 46 000 | ||||||
| 2016-08-10 | 2016-08-08 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 0,4850 | -10 484 | -5 | 26 994 | ||||
| 2016-08-10 | 2016-08-08 | 4 | SEYMOUR TAMARA A By Trust | SGNL | Common Stock | I | 23 000 | 37 478 | ||||||
| 2016-06-30 | 2016-06-28 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | -124 251 | 0 | |||||
| 2016-06-30 | 2016-06-28 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,4600 | -64 835 | -30 | 474 530 | ||||
| 2016-06-30 | 2016-06-28 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 124 251 | 539 365 | ||||||
| 2016-06-20 | 2016-06-15 | 4 | Gonyer David A | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18 000 | 18 000 | |||||
| 2016-06-20 | 2016-06-15 | 4 | Schuling Douglas A | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18 000 | 18 000 | |||||
| 2016-06-20 | 2016-06-15 | 4 | Smith Robin L | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18 000 | 18 000 | |||||
| 2016-06-20 | 2016-06-15 | 4 | LEBOW BENNETT S | SGNL | Stock Option (Right to Buy) | D | 0,51 | 18 000 | 18 000 | |||||
| 2016-05-19 | 2016-03-28 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | 200 000 | 200 000 | |||||
| 2016-05-19 | 2016-03-28 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | 0,00 | 100 000 | 100 000 | |||||
| 2016-02-12 | 2016-02-11 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | 0,00 | -124 252 | 124 251 | |||||
| 2016-02-12 | 2016-02-11 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,4600 | -54 268 | -25 | 415 114 | ||||
| 2016-02-12 | 2016-02-11 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 124 252 | 469 382 | ||||||
| 2015-11-23 | 2015-11-20 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,8000 | 7 000 | 6 | 345 130 | ||||
| 2015-11-23 | 2015-11-19 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 0,7800 | 7 000 | 5 | 338 130 | ||||
| 2015-08-14 | 2015-08-12 | 4 | SEYMOUR TAMARA A | SGNL | Employee Stock Option (Right to Buy) | D | 1,57 | 60 000 | 60 000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18 000 | 18 000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Restricted Stock Units | D | -4 125 | 0 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Common Stock | D | 5 000 | 10 500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Gonyer David A | SGNL | Common Stock | D | 4 125 | 5 500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18 000 | 18 000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Restricted Stock Units | D | -4 125 | 0 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Common Stock | D | 5 000 | 10 500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Schuling Douglas A | SGNL | Common Stock | D | 4 125 | 5 500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18 000 | 18 000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Restricted Stock Units | D | -4 125 | 0 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Common Stock | D | 5 000 | 10 500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | Smith Robin L | SGNL | Common Stock | D | 4 125 | 5 500 | ||||||
| 2015-08-10 | 2015-08-06 | 4 | LEBOW BENNETT S | SGNL | Stock Option (Right to Buy) | D | 1,62 | 18 000 | 18 000 | |||||
| 2015-08-10 | 2015-08-06 | 4 | LEBOW BENNETT S | SGNL | Common Stock | D | 5 000 | 5 000 | ||||||
| 2015-08-05 | 2015-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | -23 000 | 69 000 | ||||||
| 2015-08-05 | 2015-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Common Stock | D | 1,5600 | -8 522 | -13 | 14 478 | ||||
| 2015-08-05 | 2015-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Common Stock | D | 23 000 | 23 000 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Smith Robin L | SGNL | Restricted Stock Units | D | -1 375 | 4 125 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Smith Robin L | SGNL | Common Stock | D | 1 375 | 1 375 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Schuling Douglas A | SGNL | Restricted Stock Units | D | -1 375 | 4 125 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Schuling Douglas A | SGNL | Common Stock | D | 1 375 | 1 375 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Gonyer David A | SGNL | Restricted Stock Units | D | -1 375 | 4 125 | ||||||
| 2015-07-21 | 2015-07-17 | 4 | Gonyer David A | SGNL | Common Stock | D | 1 375 | 1 375 | ||||||
| 2015-06-23 | 2015-06-19 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | -124 252 | 248 503 | ||||||
| 2015-06-23 | 2015-06-19 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 1,5100 | -46 036 | -70 | 331 130 | ||||
| 2015-06-23 | 2015-06-19 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 124 252 | 377 166 | ||||||
| 2015-04-10 | 2015-04-08 | 4 | Riccitelli Samuel D | SGNL | Restricted Stock Units | D | -372 756 | 372 755 | ||||||
| 2015-04-10 | 2015-04-08 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 2,0800 | -119 842 | -249 | 252 914 | ||||
| 2015-04-10 | 2015-04-08 | 4 | Riccitelli Samuel D | SGNL | Common Stock | D | 372 756 | 372 756 | ||||||
| 2014-08-04 | 2014-08-04 | 4 | SEYMOUR TAMARA A | SGNL | Restricted Stock Units | D | 92 000 | 92 000 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Smith Robin L | SGNL | Restricted Stock Units | D | 5 500 | 5 500 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Smith Robin L | SGNL | Stock Option (right to buy) | D | 5,60 | 6 000 | 6 000 | |||||
| 2014-07-21 | 2014-07-17 | 4 | Gonyer David A | SGNL | Restricted Stock Units | D | 5 500 | 5 500 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Gonyer David A | SGNL | Stock Option (right to buy) | D | 5,60 | 6 000 | 6 000 | |||||
| 2014-07-21 | 2014-07-17 | 4 | Schuling Douglas A | SGNL | Restricted Stock Units | D | 5 500 | 5 500 | ||||||
| 2014-07-21 | 2014-07-17 | 4 | Schuling Douglas A | SGNL | Stock Option (right to buy) | D | 5,60 | 6 000 | 6 000 | |||||
| 2014-06-17 | 3 | LEBOW ALPHA, LLLP By LeBow Alpha, LLLP | SGNL | Common Stock, par value $0.01 per share | I | 4 465 258 | ||||||||
| 2014-06-17 | 3 | LEBOW ALPHA, LLLP By LeBow Alpha, LLLP | SGNL | Common Stock, par value $0.01 per share | I | 4 465 258 | ||||||||
| 2014-06-17 | 3 | LEBOW ALPHA, LLLP By LeBow Alpha, LLLP | SGNL | Common Stock, par value $0.01 per share | I | 4 465 258 |
P
Otwarty rynek lub prywatny zakup niepochodnych lub pochodnych papierów wartościowych
S
Otwarty rynek lub prywatna sprzedaż niepochodnych lub pochodnych papierów wartościowych
A
Grant, nagroda lub inne nabycie papierów wartościowych od spółki (np. opcja)
C
Konwersja instrumentu pochodnego
D
Sprzedaż lub przeniesienie papierów wartościowych z powrotem do spółki
F
Zapłata ceny wykonania lub zobowiązania podatkowego z wykorzystaniem części papierów wartościowych otrzymanych od spółki
G
Darowizna papierów wartościowych przez lub na rzecz insidera
K
Swapy kapitałowe i podobne transakcje zabezpieczające
M
Wykonanie lub konwersja pochodnego papieru wartościowego otrzymanego od spółki (takiego jak opcja)
V
Transakcja dobrowolnie zgłoszona na Formularzu 4
J
Inne (wraz z przypisem opisującym transakcję)
